DIEDRA THIES: Open Payments
NPI 1790135481 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$710 in 38 payments from 19 companies in 2025. Trend: 2023 $769 · 2024 $471 · 2025 $710
Food & beverage: $710
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 7 | $161 |
| Otsuka America Pharmaceutical, Inc. | 8 | $142 |
| AstraZeneca Pharmaceuticals LP | 5 | $82 |
| Lundbeck LLC | 2 | $32 |
| Astellas Pharma US Inc | 1 | $28 |
| Amgen Inc. | 2 | $28 |
| Medtronic, Inc. | 1 | $25 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $22 |
| BioMarin Pharmaceutical Inc. | 1 | $22 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
Products named: REXULTI, QULIPTA, UBRELVY, VRAYLAR, Veozah, EVENITY, SYMPLICITY G3, CAPLYTA.
Industry payments across NE — which companies pay providers there.
